Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of

#ADAG Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

www.stocktitan.net/news/ADAG/adagene-announ...

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months 4% overall discontinuation rate, no dose limiting

#ADAG Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ADAG/adagene-report...

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA Adagene (Nasdaq: ADAG) announced that muzastotug (ADG126), a masked anti-CTLA-4 antibody, will be highlighted in two poster presentations at the AACR Annual Meeting in San Diego, April 17-22, 2026.Presentations are scheduled April 20, 2026 at 9:00 AM PT in Poster Sections 50 and 51 (Poster Board 14), covering a Ph1b evaluation in MSS colorectal cancer and phase 1b/2 Morpheus Liver study results in unresectable or metastatic HCC.

#ADAG Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

www.stocktitan.net/news/ADAG/adagene-s-muza...

Adagene Provides Business Update and 2026 Objectives Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027 SAN DIEGO and SUZHOU, China, Jan.

#ADAG Adagene Provides Business Update and 2026 Objectives

www.stocktitan.net/news/ADAG/adagene-provid...

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) Adagene (Nasdaq: ADAG) announced that the U.S. FDA granted Fast Track Designation to muzastotug (ADG126) in combination with pembrolizumab for adult patients with MSS metastatic colorectal cancer without active liver metastases on Dec 16, 2025. The designation cites emerging clinical evidence of encouraging efficacy, deep durable responses, and a favorable safety profile in heavily pretreated patients. Fast Track may enable more frequent FDA interactions and rolling review. Adagene is conducting a randomized Phase 2 (10 mg/kg vs 20 mg/kg; up to 30 patients per arm; primary endpoint ORR) and plans a Phase 3 with OS as primary endpoint and a registration trial planned to begin in 2027.

#ADAG Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

www.stocktitan.net/news/ADAG/adagene-announ...

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Adagene (Nasdaq: ADAG) and Third Arc Bio announced a licensing agreement on Nov 13, 2025 for two masked CD3 T cell engagers using Adagene’s SAFEbody technology.Third Arc Bio receives worldwide rights to research, develop and commercialize two candidate molecules; Adagene receives a $5 million upfront payment, is eligible for up to $840 million in development and commercial milestones if all conditions are met, and will earn royalties on end-user sales. Adagene retains a no-cost option to develop and commercialize these candidates in Greater China, Singapore and South Korea.

#ADAG Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

www.stocktitan.net/news/ADAG/adagene-announ...

Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program Biotech firm Adagene partners with Exelixis to develop masked antibody-drug conjugate for solid tumors using SAFEbody platform. Phase 2 trial of lead candidate ADG126 starting end-2025.

#ADAG Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

www.stocktitan.net/news/ADAG/adagene-expand...

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China Adagene (Nasdaq: ADAG) announced that its ADG126 (muzastotug) therapy will be featured in two oral presentations at the 2025 CSCO Meeting in Jinan, China from September 10-14. The presentations will highlight ADG126's combination with pembrolizumab in treating microsatellite stable (MSS) colorectal cancer.The masked anti-CTLA-4 therapy has shown promising results in Phase 1b/2 trials, achieving an objective response rate of ~30% with durable response and over 80% disease control in refractory/resistant MSS CRC patients with no liver metastasis. The treatment demonstrated a median overall survival of 19.4 months in the 10 mg/kg cohorts, while maintaining less than 20% Grade 3 treatment-related adverse events.

#ADAG Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

www.stocktitan.net/news/ADAG/adagene-s-adg1...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stock with strong volume gains, Tue Jul 15th- #LSTA #KZR #IKNA #HTOO #DXPE #CMBM #CELU #BWEN #ADAG #ZKIN #XAGE #UCL #RAPT #MSGM #MNY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics Adagene licenses proprietary antibody tech to ConjugateBio for novel bispecific ADC development in growing $30B market. Get deal terms and strategic implications.

#ADAG Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

www.stocktitan.net/news/ADAG/adagene-and-co...

Adagene announces up to $25 million strategic investment from Sanofi Adagene (NASDAQ:ADAG), a developer of antibody-based therapies, has secured a strategic investment of up to $25 million from Sanofi (Euronext: SAN FP). The investment strengthens their existing partnership and includes Sanofi's exercise of an option for a third SAFEbody discovery program.The funding will support Adagene's R&D activities, particularly the clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer. Additionally, Sanofi will sponsor a phase 1/2 clinical trial evaluating muzastotug in combination with other anticancer therapies in over 100 advanced solid tumor patients.As of December 31, 2024, Adagene reported cash and cash equivalents of $85.2 million. With Sanofi's investment, the company expects to extend its cash runway into 2027. The partnership will be further strengthened by the addition of a Sanofi representative to Adagene's Scientific Advisory Board.

#ADAG Adagene announces up to $25 million strategic investment from Sanofi

www.stocktitan.net/news/ADAG/adagene-announ...

#ADAG

Groundbreaking Cancer Treatment Results: Adagene's ADG126 Clinical Trial Data Coming to ASCO 2025 Latest Phase 1b/2 results reveal ADG126's potential in advanced MSS CRC treatment when combined with Pembrolizumab. See breakthrough efficacy data.

#ADAG Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

www.stocktitan.net/news/ADAG/adagene-announ...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tue Apr 15th - #RPID #TRVI #NG #MSGM #LEDS #INVA #HITI #GNPX #ENSC #VINC #RBBN #CSLR #ADAG #ZVIA #UTZ #PRG #FUBO #FBMS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update Adagene (NASDAQ: ADAG) reported its full year 2024 financial results, highlighting significant progress in its clinical programs. The company's Muzastotug Phase 2 dose expansion study showed a 33% overall response rate in MSS CRC patients using a 20 mg/kg loading dose regimen.Key financial metrics include a cash balance of $85.2 million providing runway into late 2026, net revenue of $0.1 million (down from $18.1 million in 2023), and reduced R&D expenses of $28.8 million (21% decrease from 2023). The company reported a net loss of $33.4 million for 2024.Pipeline highlights include promising results for ADG126 in combination with pembrolizumab, showing good tolerability with only a 6% discontinuation rate. The company is advancing its SAFEbody technology platform, with two T cell engager programs: ADG138 (HER2-targeted) and ADG152 (CD20-targeted) in development.Ongoing collaborations with Exelixis, Sanofi, and Roche continue to progress, with milestone payments received and potential future payments totaling up to $2.5 billion plus tiered royalties.

#ADAG Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ADAG/adagene-report...

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer Adagene (NASDAQ: ADAG) has announced an investigator initiated Phase 2 neoadjuvant trial of ADG126 for stage II or III colorectal cancer patients. The trial, identified as NCT06846268, will begin enrollment in April 2025 with expected primary completion in mid-2027.The study will evaluate ADG126 in combination with KEYTRUDA® before surgery, with a primary endpoint measuring Major Pathologic Response (MPR) in up to 20 patients. MPR is defined as ≤10% residual viable tumor in surgical specimens. Secondary endpoints include complete pathological response, disease-free survival, and safety/tolerability.Led by Dr. Yong Wei Peng from the National University Cancer Institute, Singapore, the trial will also explore pharmacodynamic effects on the tumor microenvironment's immune profile and ADG126's pharmacokinetic profile in tumor tissues.

#ADAG Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

www.stocktitan.net/news/ADAG/adagene-announ...